The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.

“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD. Six-month ...

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD. The final patient visit has been ...

"A 14-month delay in disease progression is a very meaningful end point to our patients, because that basically means delay in symptoms, delay in fractures, [and] delay in pain in the ...

Darolutamide plus ADT and docetaxel improved overall survival and delayed mCRPC and subsequent therapy initiation in mHSPC patients, regardless of age. The study showed consistent efficacy benefits in ...

"I'm so excited about them finally removing this boxed warning," says Helen L. Bernie, DO, MPH. The FDA’s recent announcement of class-wide labeling changes for testosterone products was met with ...

An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced ...

"In terms of how I select patients, I really look at the timing of metastatic disease, so whether it's metachronous or synchronous and the volume, and I think at this stage, the data are most robust ...

Total detection rate was 36% (13/36) in the ultra-low PSA group and 51% (47/93) in the low-PSA group.

“Interestingly, the patients that were more likely to follow-up were those patients that were seen and established within our urology clinic,” says Christina B. Ching, MD. In this interview, Christina ...

The test can provide results in 48 minutes for diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.

At 24 months, 79% of patients experienced a response to therapy, and 56% achieved at least a 75% reduction in UUI episodes.